Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic
  • Search Hotels in Sausalito

  • ROOMS:

1 Drug Store Stock to Purchase Over Walgreens

Drug store stock CVS Health (CVS) outperformed Walgreens (WBA) over the past year. Moreover, Wall Street analysts expect CVS to see a better upside than WBA in the upcoming months because of its stronger fundamentals. So, it appears to be a better buy now. Keep reading…

Health services provider CVS Health Corporation (CVS) has lost 9.9% over the past month amid the broader market sell-off. However, the healthcare sector’s resilience to uncertain economic conditions and the company’s solid fundamentals have helped the stock deliver 8.8% returns over the past year.

On the other hand, pharmacy retailer Walgreens Boots Alliance, Inc. (WBA) could not survive the challenges faced by the market well and lost 31.6% over the past year. The company’s poor fundamentals are the key reason behind its underperformance.

WBA’s sales came in at $32.45 billion for the quarter ended August 31, 2022, down 5.3% year-over-year. Its net loss came in at $415 million compared to an income of $627 million a year ago. Its loss per share came in at $0.48 compared to an EPS of $0.72 in the year-ago period.

Given CVS’ fundamental strength, Wall Street analysts expect the stock to hit $122.31 in the near term, indicating a potential upside of 33%, which is much higher than what WBA could see.

Here is what could shape CVS’ performance in the near term:

Solid Financials

CVS’ total revenues increased 11% year-over-year to $80.64 billion for the second quarter ended June 30, 2022. Its net income came in at $2.95 billion, up 6% year-over-year, while its EPS came in at $2.23, up 6.2% year-over-year. Moreover, its operating income came in at $4.57 billion, up 5.6% year-over-year.

Attractive Valuations

CVS’ forward EV/Sales of 0.57x is 84.9% lower than the industry average of 3.80x. Its forward EV/EBITDA of 8.94x is 31% lower than the industry average of 12.94x. Also, its forward Price/Sales of 0.39x is 91.2% lower than the industry average of 4.38x, while its forward Price/Book of 1.51x is 40.2% lower than the industry average of 2.53x.

Robust Profitability Margins

CVS’ trailing-12-month EBITDA margin of 6.14% is 86.4% higher than the industry average of 3.29%. Its trailing-12-month net income margin of 2.66% is higher than the negative industrial average of 2.69%.

In addition, its trailing-12-month ROCE, ROTC, and ROTA of 11.00%, 5.96%, and 3.55%, compared with the industry averages of negative 38.60%, 21.31%, and 29.63%, respectively.

POWR Ratings Reflect Promising Outlook

CVS has an overall rating of A, which equates to a Strong Buy in our proprietary POWR Ratings system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.

The stock has a B grade for Growth, consistent with its solid financials in the latest reported quarter. It has a B grade for Stability, in sync with its beta of 0.71.

In the 4-stock Medical – Drug Stores industry, CVS is ranked first.

Click here for the additional POWR Ratings for CVS (Value, Momentum, Sentiment, Quality).

View all the top stocks in the Medical – Drug Stores industry here.

Bottom Line

While WBA delivered a poor performance in the last reported quarter, CVS’ financials have witnessed stable growth. Moreover, CVS’ revenue is expected to increase 6.9% year-over-year to $312.35 billion in 2022. Its EPS is estimated to grow 6.2% per annum for the next five years.

Given the stock’s sturdy financials and robust profitability, I think CVS could be a better Buy than WBA.

CVS shares were unchanged in after-hours trading Wednesday. Year-to-date, CVS has declined -9.69%, versus a -21.52% rise in the benchmark S&P 500 index during the same period.

About the Author: Riddhima Chakraborty

Riddhima is a financial journalist with a passion for analyzing financial instruments. With a master's degree in economics, she helps investors make informed investment decisions through her insightful commentaries.


The post 1 Drug Store Stock to Purchase Over Walgreens appeared first on
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 & California Media Partners, LLC. All rights reserved.